Quarterly ResultMay 18, 2026, 05:02 PM
CervoMed Q1 Net Loss $8.0M; Cash Runway into Sept 2026
AI Summary
CervoMed Inc. reported a net loss of $8.0 million for Q1 2026, an increase from $4.9 million in Q1 2025, primarily due to decreased grant revenue and higher operating expenses. The company's cash, cash equivalents, and marketable securities stood at $12.9 million as of March 31, 2026, providing a cash runway into September 2026. Despite financial challenges, CervoMed made significant clinical progress, including finalizing the Phase 3 trial design for neflamapimod in Dementia with Lewy Bodies (DLB) and presenting positive MRI and biomarker data, though the trial is subject to financing.
Key Highlights
- Q1 2026 net loss increased to $8.0 million from $4.9 million in Q1 2025.
- Cash, cash equivalents, and marketable securities were $12.9 million as of March 31, 2026.
- Anticipated cash runway extends into September 2026.
- R&D expenses rose to $5.1 million in Q1 2026 from $4.8 million in Q1 2025.
- G&A expenses increased to $3.0 million in Q1 2026 from $2.4 million in Q1 2025.
- Finalized Phase 3 trial design for neflamapimod in DLB, subject to financing.
- Presented MRI data showing neflamapimod may increase basal forebrain size/function in DLB.
- European patent issued for p38α MAP kinase inhibitors for DLB, expiring 2040.
Price Impact
More from CRVO